Validated in a CAP-accredited and CLIA-certified lab using Next Generation Sequencing methods, the test is a tool that gives a comprehensive analysis of 30 genes associated with the most common hereditary cancers: breast, colorectal, melanoma, pancreatic, prostate, ovarian, stomach and uterine. Reports integrate guidelines to assist in the development of personalised screening and prevention plans for patients. The product has performed blinded validation studies and all genetic variants were detected with >99% accuracy.